Invesco Ltd is a global investment management firm that specializes in providing a wide range of investment solutions and services to institutional and retail clients. The company offers various products, including mutual funds, exchange-traded funds (ETFs), and private investment portfolios, designed to meet the diverse needs of investors. Invesco's investment strategies span multiple asset classes, including equities, fixed income, real estate, and alternative investments, and they emphasize a client-centered approach focused on delivering long-term financial results. Additionally, the firm is committed to responsible investment practices and incorporates environmental, social, and governance (ESG) factors into its investment decisions, aiming to create sustainable value for its clients and the broader community. Read More
Tech stocks broke out this week as the QQQ neared record highs. Microsoft, Atlassian, and Hewlett Packard Enterprise show supportive fundamentals and technical setups that could extend gains if the sector's momentum holds.
Triada Networks named a finalist in the 2026 MSP Titans of the Industry Awards (Finance/Banking category), recognizing its cybersecurity and compliance work for SEC-registered investment advisers, PE firms, and hedge funds. Winners announced December 9, 2026, at the Beverly Hilton in Beverly Hills, CA.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
Vanguard's ultra-low 0.06% expense ratio appeals to cost-conscious investors, while Invesco's small-cap strategy delivered 22.3% returns over the past year.
PPA targets legacy hardware with broader industrial exposure and stronger one-year returns, while SHLD emphasizes emerging tech and cybersecurity at lower cost.
SpaceX's Nasdaq-100 weighting will more than double at the Sept. 18 rebalance as lockup expirations expand its float, forcing index funds to buy billions in shares.
PPH offers concentrated pharma exposure with 1.9% yield and lower volatility, while RSPH provides broader diversification across 60 healthcare holdings.
Invesco’s 33.6% return over the past six months has outpaced the S&P 500 by 20.8%, and its stock price has climbed to $31.99 per share. This was partly thank...
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...
Broad diversification and lower costs favor iShares, but Invesco's concentrated biotech bet delivered 47% returns in one year—at the cost of steeper drawdowns.
